Context Therapeutics Announces Positive Interim Data for CTIM-76
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 15 2026
0mins
Context Therapeutics announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer. The data are as of a May 29 data cutoff from the ongoing CTIM-76 Phase 1 study. "We are encouraged by the continued development of CTIM-76 as a potentially best-in-class CLDN6 T cell engager that may offer a much-needed new therapeutic approach for patients with platinum-resistant ovarian cancer," said Martin Lehr, Chief Executive Officer of Context. "In our first clinical presentation of dose-escalation data, weekly administration of CTIM-76 produced compelling anti-tumor activity and a well-tolerated safety profile in heavily pretreated patients, many of whom had extensive prior exposure to antibody-drug conjugates. Building on this encouraging data, we have advanced into the next phase of development, where we will evaluate CTIM-76 administered every three weeks. These results are expected to inform subsequent Phase 1b dose expansion in 2027."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTX
Wall Street analysts forecast CNTX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.580
Low
4.00
Averages
5.25
High
7.00
Current: 0.580
Low
4.00
Averages
5.25
High
7.00
About CNTX
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CTIM-76 Early Data Triggers Stock Plunge
- Clinical Data Response: Context Therapeutics reported that initial data from CTIM-76 indicated a 29% confirmed response rate among ovarian cancer patients in a cohort of 21 CLDN6-positive tumor patients, showcasing competitive activity despite a modest overall response rate after a median of seven prior therapies.
- Severe Market Reaction: The company's stock plummeted 51% on Monday, marking its worst day ever, yet analysts view the selloff as a buying opportunity, maintaining optimism for future data improvements and potential recovery in stock performance.
- Analyst Insights: H.C. Wainwright analyst Emily Bodnar maintains a 'Buy' rating with a $5 price target, highlighting CTIM-76's competitive activity in a challenging patient population, particularly among those previously treated with antibody-drug conjugates.
- Future Catalysts: Context Therapeutics plans to release initial clinical data for CT-95 in September 2026 and expects to begin dosing the first patient in an early-stage study of CT-202 in the third quarter, indicating ongoing commitment to its research and development pipeline.
See More
CTIM-76 Shows Promising Interim Results in Ovarian Cancer Trial
- Clinical Trial Progress: Context Therapeutics Inc. reported early signs of anti-tumor activity in its ongoing Phase 1 trial of CTIM-76 for heavily pretreated ovarian cancer patients, with 29% of evaluable patients (2 out of 7) achieving confirmed partial responses and 57% (4 out of 7) achieving disease control, indicating the drug's potential in treating this challenging condition.
- Patient Background: As of the May 29, 2026 data cutoff, participants had a median of seven prior therapies, highlighting the urgent need for new treatment options in a population that has limited choices after multiple treatment failures.
- Safety Assessment: Cytokine Release Syndrome (CRS) occurred in only 11% of ovarian cancer patients treated with CTIM-76, all at Grade 1 severity, suggesting a manageable safety profile at active doses, which enhances the drug's clinical applicability.
- Future Development Plans: The company plans to transition CTIM-76 to a once-every-three-weeks dosing schedule in the second half of 2026 and expects to initiate a Phase 1b expansion study in 2027, with FDA Fast Track Designation reflecting the significant need for new treatment options.
See More
Context Therapeutics Reports Positive Interim Data for CTIM-76 in Ovarian Cancer
- Clinical Trial Results: Context Therapeutics' CTIM-76 demonstrated a 29% overall response rate in platinum-resistant ovarian cancer patients who had undergone a median of seven prior therapies, indicating significant anti-tumor activity and potential as a new treatment option for these patients.
- Safety Analysis: In the clinical trial of CTIM-76, Cytokine Release Syndrome (CRS) occurred in only 11% of patients, all at Grade 1, showcasing the drug's favorable tolerability and supporting future outpatient dosing strategies.
- Pharmacokinetic Support: The pharmacokinetic profile of CTIM-76 indicates dose-dependent increases in exposure, which supports the exploration of a Q3W dosing schedule in the second half of 2026, potentially optimizing treatment regimens and enhancing patient compliance.
- Future Development Plans: The company plans to conduct a Phase 1b clinical trial expansion for CTIM-76 in 2027, building on the current positive clinical data to further evaluate its efficacy and safety in platinum-resistant ovarian cancer patients.
See More
Context Therapeutics Grants Stock Options to New Employee
- Stock Option Grant: Context Therapeutics awarded 146,000 stock options to a new employee on June 8, 2026, with an exercise price of $1.71 per share, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Details: The stock options were granted outside of the 2021 Long-Term Performance Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's flexibility and innovation in talent acquisition.
- Vesting Arrangement: The stock options have a four-year vesting period, with one-fourth vesting on the first anniversary and the remainder vesting in monthly installments, ensuring continued employee contribution during their service.
- Strategic Company Goals: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, and the stock option grant aids in attracting and retaining key talent to advance its innovative drug portfolio.
See More
Context Therapeutics Grants Stock Options to New Employee
- Conference Presentation: Context Therapeutics is scheduled to present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Stock Option Grant: The company has granted a non-qualified stock option award for 146,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4), with an exercise price of $2.63 per share, aimed at attracting and retaining talent to strengthen the team for future R&D efforts.
- Option Details: These stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, ensuring continued employee contribution during their tenure with the company.
- Strategic Goals: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, aiming to build an innovative therapeutic portfolio that enhances the company's competitiveness in the rapidly evolving biopharmaceutical market.
See More
Context Therapeutics Reports Q1 Financials with Cash Position Update
- Cash Position: As of March 31, 2026, Context Therapeutics reported cash and cash equivalents of $54.5 million, down from $66.0 million at December 31, 2025, with expectations that this will fund operations into mid-2027, ensuring financial stability for the upcoming year.
- R&D Expense Increase: The company incurred $7.0 million in research and development expenses in Q1 2026, a 100% increase from $3.5 million in Q1 2025, indicating a strong commitment to accelerating product development to meet market demands.
- Slight Rise in G&A Costs: General and administrative expenses rose to $2.3 million in Q1 2026 from $2.1 million in Q1 2025, reflecting ongoing investments in operational management, which, while modest, underscore the company's focus on governance.
- Decline in Other Income: Other income decreased to $0.7 million in Q1 2026 from $1.0 million in Q1 2025, primarily due to lower interest income from cash and cash equivalents, which may exert some pressure on the company's overall profitability.
See More
CTIM-76 Early Data Triggers Stock Plunge
- Clinical Data Response: Context Therapeutics reported that initial data from CTIM-76 indicated a 29% confirmed response rate among ovarian cancer patients in a cohort of 21 CLDN6-positive tumor patients, showcasing competitive activity despite a modest overall response rate after a median of seven prior therapies.
- Severe Market Reaction: The company's stock plummeted 51% on Monday, marking its worst day ever, yet analysts view the selloff as a buying opportunity, maintaining optimism for future data improvements and potential recovery in stock performance.
- Analyst Insights: H.C. Wainwright analyst Emily Bodnar maintains a 'Buy' rating with a $5 price target, highlighting CTIM-76's competitive activity in a challenging patient population, particularly among those previously treated with antibody-drug conjugates.
- Future Catalysts: Context Therapeutics plans to release initial clinical data for CT-95 in September 2026 and expects to begin dosing the first patient in an early-stage study of CT-202 in the third quarter, indicating ongoing commitment to its research and development pipeline.
See More
CTIM-76 Shows Promising Interim Results in Ovarian Cancer Trial
- Clinical Trial Progress: Context Therapeutics Inc. reported early signs of anti-tumor activity in its ongoing Phase 1 trial of CTIM-76 for heavily pretreated ovarian cancer patients, with 29% of evaluable patients (2 out of 7) achieving confirmed partial responses and 57% (4 out of 7) achieving disease control, indicating the drug's potential in treating this challenging condition.
- Patient Background: As of the May 29, 2026 data cutoff, participants had a median of seven prior therapies, highlighting the urgent need for new treatment options in a population that has limited choices after multiple treatment failures.
- Safety Assessment: Cytokine Release Syndrome (CRS) occurred in only 11% of ovarian cancer patients treated with CTIM-76, all at Grade 1 severity, suggesting a manageable safety profile at active doses, which enhances the drug's clinical applicability.
- Future Development Plans: The company plans to transition CTIM-76 to a once-every-three-weeks dosing schedule in the second half of 2026 and expects to initiate a Phase 1b expansion study in 2027, with FDA Fast Track Designation reflecting the significant need for new treatment options.
See More
Context Therapeutics Reports Positive Interim Data for CTIM-76 in Ovarian Cancer
- Clinical Trial Results: Context Therapeutics' CTIM-76 demonstrated a 29% overall response rate in platinum-resistant ovarian cancer patients who had undergone a median of seven prior therapies, indicating significant anti-tumor activity and potential as a new treatment option for these patients.
- Safety Analysis: In the clinical trial of CTIM-76, Cytokine Release Syndrome (CRS) occurred in only 11% of patients, all at Grade 1, showcasing the drug's favorable tolerability and supporting future outpatient dosing strategies.
- Pharmacokinetic Support: The pharmacokinetic profile of CTIM-76 indicates dose-dependent increases in exposure, which supports the exploration of a Q3W dosing schedule in the second half of 2026, potentially optimizing treatment regimens and enhancing patient compliance.
- Future Development Plans: The company plans to conduct a Phase 1b clinical trial expansion for CTIM-76 in 2027, building on the current positive clinical data to further evaluate its efficacy and safety in platinum-resistant ovarian cancer patients.
See More
Context Therapeutics Grants Stock Options to New Employee
- Stock Option Grant: Context Therapeutics awarded 146,000 stock options to a new employee on June 8, 2026, with an exercise price of $1.71 per share, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Details: The stock options were granted outside of the 2021 Long-Term Performance Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's flexibility and innovation in talent acquisition.
- Vesting Arrangement: The stock options have a four-year vesting period, with one-fourth vesting on the first anniversary and the remainder vesting in monthly installments, ensuring continued employee contribution during their service.
- Strategic Company Goals: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, and the stock option grant aids in attracting and retaining key talent to advance its innovative drug portfolio.
See More
Context Therapeutics Grants Stock Options to New Employee
- Conference Presentation: Context Therapeutics is scheduled to present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Stock Option Grant: The company has granted a non-qualified stock option award for 146,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4), with an exercise price of $2.63 per share, aimed at attracting and retaining talent to strengthen the team for future R&D efforts.
- Option Details: These stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, ensuring continued employee contribution during their tenure with the company.
- Strategic Goals: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, aiming to build an innovative therapeutic portfolio that enhances the company's competitiveness in the rapidly evolving biopharmaceutical market.
See More
Context Therapeutics Reports Q1 Financials with Cash Position Update
- Cash Position: As of March 31, 2026, Context Therapeutics reported cash and cash equivalents of $54.5 million, down from $66.0 million at December 31, 2025, with expectations that this will fund operations into mid-2027, ensuring financial stability for the upcoming year.
- R&D Expense Increase: The company incurred $7.0 million in research and development expenses in Q1 2026, a 100% increase from $3.5 million in Q1 2025, indicating a strong commitment to accelerating product development to meet market demands.
- Slight Rise in G&A Costs: General and administrative expenses rose to $2.3 million in Q1 2026 from $2.1 million in Q1 2025, reflecting ongoing investments in operational management, which, while modest, underscore the company's focus on governance.
- Decline in Other Income: Other income decreased to $0.7 million in Q1 2026 from $1.0 million in Q1 2025, primarily due to lower interest income from cash and cash equivalents, which may exert some pressure on the company's overall profitability.
See More
